Recommend Lupin in pharmaceutical space: G Chokkalingam
"They had more than doubling the US officials employed at FDA in India so I do not know whether how many companies are going to inspect."
By 
| Updated:
| Updated: 
In a chat with ET Now, G Chokkalingam, Founder, Equinomics Research & Advisory Pvt Ltd, shares his views on pharmaceutical sector.
ET Now: From the pharmaceutical space what is your top recommendation at this point?
G Chokkalingam: Except Lupin I would not recommend any other stock because I firmly believe that one the valuations are stretched and two if you read carefully the statements of US FDA Chief was here in the country in the recent days.
It looks little nervous. They had more than doubling the US officials employed at FDA in India so I do not know whether how many companies are going to inspect and how many more alerts are going to come, so I would be quite cautious on entire pharma space at this point in time.
ET Now: From the pharmaceutical space what is your top recommendation at this point?
G Chokkalingam: Except Lupin I would not recommend any other stock because I firmly believe that one the valuations are stretched and two if you read carefully the statements of US FDA Chief was here in the country in the recent days.
It looks little nervous. They had more than doubling the US officials employed at FDA in India so I do not know whether how many companies are going to inspect and how many more alerts are going to come, so I would be quite cautious on entire pharma space at this point in time.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
CY22 to be year of mid & smallcaps? 3 deep value ideas from G ChokkalingamADVERTISEMENT
